astrazeneca alexion presentation
march 12 (reuters) - astrazeneca azn.l: astrazeneca - to retain alexion brand and brand will be known as 'alexion, the astrazeneca rare disease unit', headquartered in boston, u.s. Alexion's franchise includes Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody. AstraZeneca will pay $60 in cash and 2.1243 AstraZeneca American Depositary Shares for each Alexion share held. Save as required by law or regulation, AstraZeneca and Alexion disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements in this announcement that may occur due to any change in their expectations or to reflect events or circumstances after the date of this announcement. Dosing is underway in Phase 3 trials of ULTOMIRIS in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ALXN2060 (AG10) in ATTR cardiomyopathy in, The Clinical Trial Approval (CTA) scheme for ALXN1820 (bi-specific anti-properdin mini-body) and the Investigational New Drug (IND) application for ALXN1850 (next generation asfotase alfa) have been accepted, in. BOSTON--(BUSINESS WIRE)--Jan. 12, 2021-- Greater scientific presence in immunology by adding Alexion's innovative complement-technology platforms and strong pipeline Dedicated rare disease unit In contrast, AstraZeneca's capabilities in genomics, precision medicine and oligonucleotides can be leveraged to develop medicines targeting less-frequent diseases. Statements in this communication regarding Alexion, AstraZeneca and the combined company that … The acquisition adds a new technology platform to AstraZeneca's science and innovation-driven strategy. For Media contacts, click here, We use cookies to give you the best online experience. The transaction is likely to complete during the third-quarter of 2021, following which, Alexion shareholders will own a 15% stake in the combined company. (viii) Unless otherwise stated all prices and closing prices for Alexion Shares and AstraZeneca Shares are derived from Bloomberg. The deal will be AstraZeneca's largest acquisition, helping it to diversify from its fast-growing cancer business into rare diseases and immunology. 1 A rare disease is a disease impacting less than 200,000 patients (as defined in the US Orphan Drug Act 1983). Elle déclare en 2017 pour cette activité des dépenses annuelles d'un montant compris entre 700 000 et 800 000 euros [ 29 ] . AstraZeneca said it is doing further research to see … AstraZeneca Mölndal presentation. AstraZeneca PLC. For Media enquiries, Megan Goulart, +18573388634, and for Investor Relations, Chris Stevo, +18573389309. Each of Alexion and AstraZeneca may also file other relevant documents with the U.S. Securities and Exchange Commission (“SEC”) regarding the proposed transaction. The two companies have been on converging paths, AstraZeneca expanding its presence from primary to speciality care, whereas Alexion has been progressing from ultra-orphan to orphan and speciality conditions. The company remains on track to reach its stated long-term ambition to treat roughly 7,500 people with generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) in the United States by year end 2025. Consequently, there can be no certainty that the completion of the proposed acquisition will be forthcoming. AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Greater scientific presence in immunology by adding Alexion's innovative complement-technology platforms and strong pipeline, Dedicated rare disease unit to be headquartered in Boston, Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care, Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio, Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend, The acquisition will be immediately core earnings-accretive and value-enhancing, and is aligned with stated capital-allocation priorities. Any failure to comply with this restriction may constitute a violation of such laws or regulations. Guidance at CER and excludes COVID-19 Vaccine AstraZeneca and Alexion… AstraZeneca’s shares slumped more than 9% on Monday after the global pharmaceuticals company announced over the weekend to acquire Alexion Pharmaceuticals for $39 billion or $175 per share in cash and stock.. That would be the biggest deal ever for the UK-based global pharmaceuticals company, but the company’s relative shortage of cash raised eyebrows. By using our website, you agree to our use of cookies in accordance with our, Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference. Guidance at CER and excludes COVID-19 Vaccine AstraZeneca and Alexion. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders of Alexion in connection with the proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus or proxy statement when it is filed with the SEC. Morgan Stanley and Goldman Sachs International are joint corporate brokers. ALEXION PHARMACEUTICALS, INC. - 10-K, Annual Report: 06.02. Buying Alexion allows AstraZeneca to significantly expand and diversify their cash-flows in the short-term. The bridge-financing facility is available for an initial term of 12 months from the earlier of the date of completion of the acquisition and 12 December 2021 with up to two six-month extensions available at the discretion of AstraZeneca. I am very proud of the hard work of all our teams who continue to be so dedicated to serving patients across the globe,” said Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion. This acquisition allows us to enhance our presence in immunology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Completion of the proposed acquisition is subject to the satisfaction of several conditions as more fully described in this announcement. Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Alexion or AstraZeneca. The acquisition also strengthens AstraZeneca's cash-flow generation, providing additional flexibility to reinvest in R&D and rapid debt reduction, with an ambition to increase the dividend. Have the opportunity to learn about the application of engineering in drug development, and lead your own 10-week project. (iv) The value placed by the acquisition on the entire issued and to be issued ordinary share capital of Alexion is to be calculated: (vi) The share capital of the combined Group (being 1,551,562,753) has been calculated as the sum of: (vii) The percentage of the share capital of the combined Group that will be owned by Alexion Shareholders is calculated by dividing the number of New AstraZeneca Shares to be issued pursuant to the terms of the acquisition referred to in paragraph (vi) above by the issued share capital of the combined Group (as set out in paragraph (vi) above) and multiplying the resulting sum by 100 to product a percentage. AstraZeneca has long been a leader in treatments for respiratory disease, but sales have stagnated. Except as explicitly stated in this announcement, none of the contents of AstraZeneca's or Alexion's websites, nor any website accessible by hyperlinks on AstraZeneca's or Alexion's websites, is incorporated in or forms part of, this announcement. Alexion will webcast its corporate presentation, given by Aradhana Sarin, M.D., Chief Financial Officer, at the 39th Annual J.P. Morgan Healthcare Conference today, Tuesday, January 12, 2021 at 7:30 a.m. Eastern Time. What to Know. AstraZeneca PLC (NASDAQ:AZN) AstraZeneca to acquire Alexion Conference Call December 12, 2020 9:00 AM ET. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency as well as the first and only approved Factor Xa inhibitor reversal agent. Alexion's executive officers are Ludwig Hantson (Chief Executive Officer), Aradhana Sarin (Chief Financial Officer), Tanisha Carino (Chief Corporate Affairs Officer), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Indrani Franchini (Chief Compliance Officer), Brian Goff (Chief Commercial and Global Operations Officer), and John Orloff (Head of Research and Development). As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). AstraZeneca remains committed to maintaining a strong investment-grade credit rating. Alexion has pioneered complement inhibition for a broad spectrum of immune-mediated rare diseases caused by uncontrolled activation of the complement system, a vital part of the immune system. The medicine is approved in many countries for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder. Core EPS is a non-GAAP financial measure and adjusted from reported GAAP EPS to exclude certain significant items such as amortisation and impairment of intangible assets, charges and provisions related to global restructuring programmes and other specified items per AstraZeneca annual filings. All US federal prisons on temporary lockdown ahead of Biden inauguration. 3 Reasons AstraZeneca's Merger With Alexion Will Work for Investors Here's why AstraZeneca's shareholders can expect healthy returns from this $39 billion investment. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. ... (CER) and for full-year (FY) 2020, unless stated otherwise. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. “For almost 30 years, Alexion has been committed to transforming the lives of those impacted by rare diseases and devastating conditions, and the company remains focused on advancing its innovative therapies and pipeline to drive value for patients and shareholders once we are part of AstraZeneca.”, Robust Portfolio Positions Alexion for Growth. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "envisages", "plans", "projects", "anticipates", "targets", "aims", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions and include, but are not limited to the ability of the parties to consummate the proposed acquisition on a timely basis or at all, the ability of the parties to satisfy the conditions precedent to consummation of the proposed acquisition, including the ability to secure the required regulatory approvals on the terms expected, at all or in a timely manner, the ability of AstraZeneca to successfully integrate Alexion's operations, and the ability of AstraZeneca to implement its plans, forecasts and other expectations with respect to Alexion's business after the completion of the proposed acquisition and realise expected synergies. Alexion remains confident in the sustainability and growth potential of its innovative pipeline. PDF 13,683KB First quarter results 2015 . (ix) The volume weighted average price of an Alexion Share is derived from Bloomberg by reference to the volume weighted average price over the last 30 Alexion trading days up to 11 December 2020 (being the last Business Day prior to announcement of an offer for Alexion). Neither this announcement nor any copy of it may be taken or transmitted directly or indirectly into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction. For Media enquiries This document is not a substitute for the proxy statement/prospectus or registration statement or any other document that Alexion or AstraZeneca may file with the SEC. Persons into whose possession this announcement or other information referred to herein should inform themselves about, and observe, any restrictions in such laws or regulations. Alexion achieved impressive revenue growth over the last few years, with revenues of $5.0bn in 2019 (21% year-on-year growth). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The acquisition of Alexion is consistent with AstraZeneca's capital-allocation priorities. The acquisition has the potential to advance the shared science-led mission of both companies to leverage complementary approaches to developing life-changing medicines. ... harbor statements including Alexion-related balance on Slide 3. ", Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. Goldman Sachs International, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, and Goldman Sachs Bank USA, which is authorised and regulated by the Board of Governors of the Federal Reserve System (Federal Reserve Board), the FDIC and the New York State Department of Financial Services, are each acting exclusively for AstraZeneca and no one else in connection with the transaction and the matters referred to in this document and will not regard any other person as a client in relation to the matters set out in this document and will not be responsible to anyone other than AstraZeneca for providing the protections afforded to their respective clients, nor for providing advice in relation to the transaction or any other matter referred to in this document. Certain figures contained in this announcement, including financial information, have been subject to rounding adjustments. As a leader in rare diseases for more than 25 years, Alexion has developed and commercialises two approved complement inhibitors to treat patients with PNH and atypical haemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalised myasthenia gravis and neuromyelitis optica spectrum disorder.